3 completed, 1 recruiting, 1 unknown. 2 Not applicable, 2 Phase 4, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Maple Leaf Research: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY Efavirenz 600mg - Hiv | Not applicable | Recruiting | University of Toronto | 26 | 2025-01-14 | 2026-03-17 |
| Drug-Drug Interaction Study in Trans Women Living With HIV Biktarvy 50/200/25 Tab, Estradiol Tablets - Hiv, Transgenderism | Phase 4 | Unknown | Maple Leaf Research | 45 | 2022-11-23 | 2024-09-26 |
| PrEP and Alcohol - Enhancing HIV Pre-Exposure Prophylaxis (PrEP) Alcohol-focused brief intervention - Hazardous Alcohol Use | Not applicable | Completed | Centre for Addiction and Mental Health | 122 | 2021-09-28 | 2025-02-10 |
| PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 Tenofovir/emtricitabine - HIV, Human Immunodeficiency Virus | Phase 4 | Completed | Unity Health Toronto | 52 | 2014-10-01 | 2016-10-17 |
| Effects of Intensive cART During Acute/Early HIV Infection raltegravir, maraviroc, emtricitabine 200mg /tenofovir 300mg - Acute HIV Infection | Phase 2 / Phase 3 | Completed | University of Toronto | 32 | 2011-11-01 | 2016-04-05 |
Acquired Immunodeficiency Syndrome (3) · Depression (1) · Substance-Related Disorders (1) · Transsexualism (1)
Emtricitabine (2) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (2) · Tenofovir (2) · Estradiol (1) · Ethanol (1) · Lopinavir (1) · Maraviroc (1) · Raltegravir Potassium (1) · Ritonavir (1) · efavirenz (1) · lopinavir-ritonavir drug combination (1)
Canada (5)
Colin Kovacs, MD (2) · Mario Ostrowski, MD (2) · Darrell Tan, MD FRCPC PhD (1) · Mona Loutfy, MD, MPH (1) · Paul A. Shuper, PhD (1)